Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 2398

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 2398
---
 team at Javelin Pharmaceuticals, Inc. from October 2008 to August 2010, which was acquired by Hospira (now Pfizer
Inc.) in 2010. Dr. Lang worked for Novartis Consumer Health from October 2006 to October 2008 and he began his career with Johnson &
Johnson (NYSE: JNJ) where he worked from 1999 to 2006. In addition, Dr. Lang serves on several boards including with Cytogel Pharmaceuticals
and the NIH/NINDS EPPIC initiative.  Dr. Lang is an Anesthesiologist and Pain Management Specialist with over 26 years of
experience in the pharmaceutical industry. During his pharmaceutical career, he has had both broad-based drug and device development
expertise in a variety of therapeutic areas. Dr. Lang has experience in designing development programs from early translational
stages through phase III including the successful filing of several recent INDs and NDAs. He has experience with regulatory interactions
and negotiations with FDA and various European and Asian Authorities. Dr. Lang received his Doctor of Medicine from Ben-Gurion
University of the Negev and completed post graduate training at Emory University in Atlanta, GA. 

Todd
Davis has served as a member of our board of directors since January 2023. He is the Chief Executive Officer of Ligand
Pharmaceuticals Incorporated since December 2022 and is a member of the board of directors since 2007. He is the founder and has
served as the managing partner of RoyaltyRx Capital, LLC, a special opportunities investment firm, since 2018. Since November
2019, he has also served as Chairman and CEO of Benuvia Holdings, LLC, a pharmaceutical holding company. From 2006 to 2018, Mr.
Davis was a founder and Managing Partner of HealthCare Royalty Partners, a global healthcare investment firm. From 2004 to 2006,
Mr. Davis was a partner at Paul Capital Partners, where he co-managed its royalty investments as a member of the Royalty Management
Committee. From 2001 to 2004, he served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners.
Mr. Davis began his business career in sales at Abbott Laboratories where he held several commercial roles of increasing responsibility.
He subsequently held general management, business development, and licensing roles at Elan Pharmaceuticals. Mr. Davis is a navy
veteran